Jeannine Thomas
Investor Relations
Replay available
Moleculin Biotech, Inc. (NASDAQ: MBRX) Q4 2023 earnings conference call, held 2024-03-25. Replay captured from the company's public earnings webcast.

Investor Relations
Chairman and Chief Executive Officer
Senior Chief Medical Officer
Executive Vice President and Chief Financial Officer
Analyst, Roth MKM
Analyst, H.C. Wainwright
Greetings. Welcome to the Moleculin Biotech 2023 year-end conference call and webcast. At this time, all participants are in a listen-only mode. The question-and-answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. Please note that this conference is being recorded. I will now turn the conference over to Jeannine Thomas, Investor Relations. Thank you. You may begin. Thank you, Daryl, and good morning and welcome, everyone. At this time, I would like to remind our listeners that remarks made during this webcast may state management's intentions, beliefs, expectations, or future projections. These are forward-looking statements and involve risks and uncertainties. Forward-looking statements on this call are made pursuant to the safe harbor provisions of the federal securities laws and are based on Moleculin's current expectations and actual results could differ materially. As a result, you should not place undue reliance on any forward-looking statements. Some of the factors that could cause actual results to differ materially from these contemplated by such forward-looking statements are discussed in the periodic reports and molecular files with the Securities and Exchange Commission. These documents are available in the investor section of the company's website and on the Securities and Exchange Commission's website. We encourage you to review these documents carefully. Additionally, certain information contained in this webcast relates to or is based on studies, publications, surveys, and other data obtained from third-party sources and the company's own estimates and research. While the company believes these third-party sources to be reliable as of t...